Acurx Pharmaceuticals (NASDAQ:ACXP) Earns “Buy” Rating from HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Acurx Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Price Performance

NASDAQ ACXP traded down $0.04 on Tuesday, hitting $1.31. 161,646 shares of the stock were exchanged, compared to its average volume of 1,112,354. The business’s fifty day moving average is $1.43 and its 200 day moving average is $2.08. Acurx Pharmaceuticals has a 52 week low of $1.27 and a 52 week high of $8.34. The company has a market capitalization of $7.26 million, a PE ratio of -0.49 and a beta of -2.02.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.15). Analysts predict that Acurx Pharmaceuticals will post -2 EPS for the current fiscal year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.